GoPro Inc vs Repligen Corporation Common Stock — how do they compare? GoPro Inc trades at $1.08 (market cap $238.34M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 47.5× GoPro Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Repligen Corporation Common Stock for 0 Days on average.
| GPRO | RGEN | |
|---|---|---|
Market Cap | $238.34M | $11.31B |
Volume | 5,242,039 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $2.31 | $194.57 |
52-Week Low | $0.58 | $102.87 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $297.12M | $11.20B |
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.18, down 0.84% on the day, following recent volatility driven by merger speculation and influencer investment. The stock shows bullish technical signals with oversold RSI conditions, while fundamentals reveal persistent challenges with negative net income margins (-28.52%) and declining revenue trends from $1.1B in 2022 to $652M in 2025. The company announced a $285 million merger with Starman Optical and received 11 industry awards for its MISSION 1 series, providing potential catalysts amid ongoing financial struggles.
Investment outlook remains highly speculative with significant execution risks. The merger offers potential upside but faces shareholder litigation over valuation concerns. Analyst consensus shows cautious sentiment with only 21% buy ratings, while cash flow deficits and competitive pressures from smartphone technology create substantial headwinds for sustainable recovery.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →